The tenosynovial giant cell tumor (TGCT) trial hit its primary endpoint, teeing up an option decision that could establish ...
Merck KGaA is shaping up to take on Daiichi Sankyo and Ono Pharma in the market for tenosynovial giant cell tumour (TGCT) ...
MERCK & Co licenced an experimental cancer antibody from a closely held Chinese company in a deal worth US$588 million ...
A subcutaneous version of Daiichi Sankyo’s AstraZeneca-partnered blockbuster antibody-drug conjugate (ADC) Enhertu could be ...
Merck (NYSE: MRK) recently reported its Q3 ... $0.24 per share related to deals with Curon Biopharmaceutical and Daiichi Sankyo. In this note, we discuss key takeaways from its recent results ...
BASKING RIDGE, N.J. & RAHWAY, N.J. - Daiichi Sankyo (TSE: 4568) and Merck (NYSE: MRK), also known as MSD outside the United States and Canada, have announced the commencement... ByInvesting.com ...
Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous ...
Daiichi Sankyo & AstraZeneca’s Enhertu receives 2024 Prix Galien USA Award for Best Biotechnology Product: Tokyo Monday, November 11, 2024, 09:00 Hrs [IST] Daiichi Sankyo and As ...
Expert: Peter Ganz, M.D., F.A.C.C.; Interviewer: Adolph M. Hutter, Jr., M.D., M.A.C.C. Despite the tremendous success of statin therapy compared to earlier lipid ...
Immunotherapy May Be Overused in Dying Cancer Patients Immunotherapy has largely replaced chemotherapy as the last resort in patients at the end of life, but it's not always the right move.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback